BDO@ASCO June 3, 2024: How Blacks Respond to Chemo Differently and Uterine Cancer Challenges

BDO is currently covering the American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL from June 1-June 3, 2024. Thank you so much for following along with our reporting and we’re looking forward to more for next year. This chemo drug may be better option for Black women with breast cancer A clinical trial study presented at ASCO focused on a chemotherapy side effect called taxane-induced peripheral neuropathy (TIPN) in Black women with breast cancer. TIPN causes numbness, tingling, and pain in the hands and feet. Researchers already knew Black women experience more TIPN with a specific drug called paclitaxel (given weekly). The study compared paclitaxel to another chemotherapy drug, docetaxel (given every 3 weeks), to see if docetaxel caused less TIPN in Black women. They also looked at genes that might influence TIPN risk, but these genes didn’t seem to have a major impact. The findings suggest docetaxel may be a better choice than paclitaxel for Black women with early-stage breast cancer because it leads to less TIPN. This could be a significant step towards reducing disparities in breast cancer treatment for Black women. However, it’s important to note that the study only looked at Black women and...